Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
A phase 2 trial of Carboplatin, Gemcitabine and Eribulin in triple-negative breast cancer, run by BioNTech SE, active and no longer recruiting.
Overview
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy is a phase 2 interventional study registered as NCT06449222 by BioNTech SE, with 83 participants enrolled, started 2024-08-26 and due to reach its primary completion in 2028-08. Interventions recorded: BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel, Carboplatin, Gemcitabine and Paclitaxel.
Similar pages
not linked directly; found by shared links- TrialROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Shares Eribulin, BioNTech, Gemcitabine, Bristol Myers Squibb and the tag pipeline.
- TrialA Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Shares Eribulin, Carboplatin, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Shares Gemcitabine, Bristol Myers Squibb, Carboplatin and the tag pipeline.
- TrialA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Shares Gemcitabine, Carboplatin, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
Shares BioNTech, Triple-negative breast cancer (TNBC) and the tag pipeline.
- TrialA Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
Shares Eribulin, Gemcitabine and the tag pipeline.
- TrialStudy of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
Shares Gemcitabine, Bristol Myers Squibb, Carboplatin and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Shares BioNTech, Bristol Myers Squibb and the tag pipeline.